SCPS vs. STAB, NOVN, NOVNQ, CALA, IGNY, HGEN, PKBO, PTEIQ, ONCSQ, and CNTX
Should you be buying Scopus BioPharma stock or one of its competitors? The main competitors of Scopus BioPharma include Statera Biopharma (STAB), Novan (NOVN), NVN Liquidation (NOVNQ), Calithera Biosciences (CALA), Ignyte Acquisition (IGNY), Humanigen (HGEN), Peak Bio (PKBO), PolarityTE (PTEIQ), OncoSec Medical (ONCSQ), and Context Therapeutics (CNTX). These companies are all part of the "medical" sector.
Statera Biopharma (NASDAQ:STAB) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership, community ranking and analyst recommendations.
Scopus BioPharma received 2 more outperform votes than Statera Biopharma when rated by MarketBeat users.
Scopus BioPharma has lower revenue, but higher earnings than Statera Biopharma.
In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.
Statera Biopharma has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500.
Summary
Scopus BioPharma beats Statera Biopharma on 3 of the 4 factors compared between the two stocks.
Get Scopus BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Scopus BioPharma Competitors List
Related Companies and Tools
